cbd vs thc for sleep

Cbd vs thc for sleep

All clinical data and information obtained for the purpose of this research that could identify participants will be treated as confidential and securely stored, adhering to the University regulations and the Australian Code for the Responsible Conduct of Research. Participant data will be identified by a unique code number that will be allocated after the participant gives consent to participate in the study. The unique code linking the participant’s identity/personal details (e.g., name, date of birth) will be stored in a password-encrypted file that will not be accessible from the internet. All data will be stored at the Woolcock Institute of Medical Research in written and computerised formats. Participant information will reside on a secure server that is regularly backed up. All data will be stored securely for at least 15 years. Only researchers affiliated with the study will have access to participant data. Study progress and safety will be monitored and evaluated internally in an ongoing fashion by the Trial Management Group consisting of the principal investigators, trial coordinator, research assistants, trial statistician, data manager and sleep clinic manager. There are no planned interim analyses. The final decision to terminate the trial lies with the principal investigators and will be based on (1) safety data and (2) target recruitment number. The investigator team will conduct an internal 3-monthly review of all adverse events and reactions and if after discussion, the rate of such events is deemed unacceptable then the study will be stopped and the human research ethics committee will be advised of the decision.

See also  best cbd companies 2021

Medical conditions that result in frequent need to get out of bed (e.g., nocturia)

Participants will have sleep physician-confirmed insomnia disorder and will be thoroughly screened to rule out other sleep disorders.

Cognitive assessment will take place the morning post-drug administration (see table 1 ), to explore the functional consequences of 10 mg THC and 200 mg CBD on next-day daytime function. This will be measured from approximately 09:00 hours using the following battery of computerised cognitive/psychomotor tasks known to be sensitive to the impairing effects of THC 60 70 : Digit Symbol Substitution Test (DSST; measure of processing speed, working memory and attention), Divided Attention Task (DAT; measure of processing speed, working memory and attention) and Paced Auditory Serial Addition Task (PASAT; measure of processing speed and sustained attention). Other cognitive tasks to be administered in conjunction include the Psychomotor Vigilance Task (PVT; simple reaction time task measuring sustained attention), Stroop test (a measure of executive functioning), and the 1- and 2-n back test (a measure of working memory and information processing).

Sample size and statistical analyses

To demonstrate feasibility of a cannabinoid study in chronic insomnia and establish clinical trial procedures for future trials in this area.

Blood will be collected once via venepuncture into EDTA vacutainer tubes (Becton, Dickinson and Company, New Jersey, USA) at approximately 08:45 hours, immediately after the driving performance task, to measure levels of THC and other cannabinoids the morning post-drug administration. Blood will be centrifuged at 1500×g for 10 min at 4°C with the supernatant plasma aliquoted and stored in 1.8 mL cryotubes at −80°C until subsequent analysis. Plasma will be analysed via LC-MS/MS according to previously published methods 85 86 for cannabinoids (CBD, THC) and their metabolites (11-OH-THC, THC-COOH; 7-COOH-CBD, 7-OH-CBD and 6-OH-CBD) as well as a range of endocannabinoid and related molecules (anandamide, 2-AG, 1-AG, oleoylethanolamide (OEA), palmitoylethanolamide (PEA), linoyl-ethanolamide (LEA) and oleamide).

See also  apartemen puncak cbd serah terima

Insomnia Severity Index (ISI) score≥15

Screening

This study uses a randomised, controlled trial design to investigate the effects of a pharmaceutical-grade oral oil solution containing 10mg Δ 9 -tetrahydrocannabinol (THC) and 200mg cannabidiol (CBD) on sleep and daytime function in a clinical population.

Insomnia symptoms for >3 times per week and present longer than 3 months

Cbd vs thc for sleep

Just as hemp seedlings are sprouting up across the United States, so is the marketing. From oils and nasal sprays to lollipops and suppositories, it seems no place is too sacred for CBD. “It’s the monster that has taken over the room,” Dr. Brad Ingram, an associate professor of pediatrics at the University of Mississippi Medical Center, said about all the wild uses for CBD now. He is leading a clinical trial into administering CBD to children and teenagers with drug-resistant epilepsy.

Cannabidiol and THC are just two of the plant’s more than 100 cannabinoids. THC is psychoactive, and CBD may or may not be, which is a matter of debate. THC can increase anxiety; it is not clear what effect CBD is having, if any, in reducing it. THC can lead to addiction and cravings; CBD is being studied to help those in recovery.

Is This A Scam?

CBD is advertised as providing relief for anxiety, depression and post-traumatic stress disorder. It is also marketed to promote sleep. Part of CBD’s popularity is that it purports to be “nonpsychoactive,” and that consumers can reap health benefits from the plant without the high (or the midnight pizza munchies).

What are the claims?

Will these trends change your life — or

See also  cbd for erectile dysfunction